Microbicides
Microbicides
Dapivirine Vaginal Ring Study Fully Enrolled, New Technology Shows Promise
- Details
- Category: HIV Prevention
- Published on Thursday, 03 July 2014 00:00
- Written by HIVandHepatitis.com
The Microbicide Trials Network (MTN) announced last week that the Phase 3 ASPIRE trial, testing a vaginal ring containing the NNRTI dapivirine for preventing sexual transmission of HIV, has completed enrollment with more than 2600 women. In related news, researchers reported promising findings from a study of a novel "pod" technology for delivering multiple drugs for HIV prevention in a vagina ring.
Microbicide Gel Protects against Vaginal or Anal Transmission of HIV and Other STIs
- Details
- Category: Microbicides
- Published on Friday, 25 April 2014 00:00
- Written by Population Council
An experimental microbicide gel known as MZC offers protection against multiple strains of HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV), and it appears safe for either vaginal or rectal use, according to an animal study by researchers at the Population Council.
CROI 2014: Dapivirine Vaginal Ring Appears Safe and Effective in Tissue Study
- Details
- Category: HIV Prevention
- Published on Tuesday, 18 March 2014 00:00
- Written by Liz Highleyman
Vaginal rings containing the experimental NNRTI dapivirine were well-tolerated and blocked HIV infection of cervical tissue samples, but rings containing maraviroc did not produce adequate drug concentrations, researchers reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this month in Boston.
CROI 2014: Self-Reports Did Not Reflect Actual Gel or Pill Use in VOICE PrEP Trial
- Details
- Category: Post-exposure Prophylaxis (PEP)
- Published on Tuesday, 25 March 2014 00:00
- Written by Microbicide Trials Network
Self-reported adherence to daily tenofovir or Truvada pills or tenofovir vaginal gel for pre-exposure prophylaxis (PrEP) against HIV infection did not match drug levels in the body, helping to explain the lack of protection seen in the VOICE trial, researchers reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this month in Boston.
HIV Integrase Inhibitor Elvitegravir Approved in European Union
- Details
- Category: Approved HIV Drugs
- Published on Thursday, 21 November 2013 00:00
- Written by Gilead Sciences
The next-generation HIV integrase inhibitor elvitegravir has been approved by the European Commission, to be marketed under the brand name Vitekta, according to an announcement this week from developer Gilead Sciences. It is indicated for use in combination antiretriviral regimens containing a ritonavir-boosted protease inhibitor.
More Articles...
- AAPS Showcases Vaginal Ring with Tenofovir + Contraceptive, Gel Suitable for Vaginal and Rectal Use
- ICAAC 2013: Tenofovir Vaginal Ring Protects Monkeys on Depo-Provera Against HIV-like Virus
- Reformulated Tenofovir Gel Found Safe and Acceptable for Anal Sex
- Lubricants for Sex Can Damage Cells, but Did Not Increase HIV Risk in Lab Study
Web Design and Development by